Mark is internationally known for his political advocacy, strategic insights and technical work on preventing fake drugs through serialization, traceability and authentication technologies. He advises senior executives on major cross-functional challenges including compliance for the EU Falsified Medicines Directive, the US Drug Supply Chain Security Act and other imminent requirements.
He worked for GlaxoSmithKline, Charles River, Quintiles, SICPA and several smaller companies before setting up his own consultancy. He has spent the past ten years in track and trace, supply chain and consumer engagement applications and is the author of "Pharmaceutical Anti-Counterfeiting" (Wiley, New York, 2011). Lately, his work involves helping corporate customers in pharmaceuticals and other sectors to link these big data areas to generate new commercial insights and improved patient outcomes.
He said: "I am delighted and honoured to be included in this list. It acknowledges the growing importance of product authenticity and data integrity in keeping patients and consumers safe."
For further information please contact [email protected]
Twitter: @StopFakeDrugs
_________________________________________________